Essex Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Essex Financial Services’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$401K	Sell	644 -121	-16%	-$82.4K	0.02%	553
2026 Q1	$591K	Buy	765 +80	+12%	+$61.2K	0.03%	412
2025 Q4	$529K	Buy	685 +109	+19%	+$74K	0.03%	425
2025 Q3	$324K	Buy	+576	New	+$326K	0.02%	560
2025 Q2	–	Sell	-410	Closed	-$260K	–	704
2025 Q1	$260K	Buy	410 +78	+23%	+$53.6K	0.02%	531
2024 Q4	$237K	Buy	332 +29	+10%	+$24.3K	0.02%	553
2024 Q3	$292K	Sell	303 -40	-12%	-$44.5K	0.02%	504
2024 Q2	$382K	Buy	343 +83	+32%	+$80.5K	0.03%	430
2024 Q1	$250K	Buy	+260	New	+$247K	0.02%	456

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Essex Financial Services's REGN Position: Q2 2026 in Review

Essex Financial Services reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, selling an estimated $82.4K and leaving 644 shares worth $401K. The position accounts for 0.02% of the portfolio, ranked #553.

Essex Financial Services first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $591K in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Essex Financial Services held 644 shares of Regeneron Pharmaceuticals worth $401K as of Q2 2026.
Essex Financial Services sold 121 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $82.4K.
Regeneron Pharmaceuticals made up 0.02% of Essex Financial Services's portfolio in Q2 2026, its #553 holding.
Essex Financial Services first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Essex Financial Services's Regeneron Pharmaceuticals position peaked at $591K in Q1 2026.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Essex Financial Services's 13F filing for Q2 2026, filed 10 Aug 2026.